Tivic Health Receives FDA Approval for Two Investigational New Drug Applications for Entolimod™ to Treat Acute Radiation Syndrome and Advanced Cancers

Reuters08-20

<a href="https://laohu8.com/S/TIVC">Tivic Health</a> Receives FDA Approval for Two Investigational New Drug Applications for Entolimod™ to Treat Acute Radiation Syndrome and Advanced Cancers

Tivic Health Systems Inc. has announced the receipt of two investigational new drug $(IND.AU)$ applications for their lead candidate, Entolimod™, from Statera Biopharma. These INDs are aimed at the treatment of acute radiation syndrome $(ARS.UK)$ and advanced cancers. The transfer of these applications facilitates Tivic's engagement with the FDA to advance Entolimod along its regulatory pathway. This development enables the pursuit of clinical trials addressing conditions such as neutropenia and lymphocyte exhaustion. Tivic's CEO, Jennifer Ernst, emphasized the company's immediate focus on Entolimod's application for acute radiation syndrome, while also exploring its potential anti-tumor effects in advanced cancer scenarios.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tivic Health Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250820053049) on August 20, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2560105142?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-20 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2560105142","market":"nz","top_or_hot":-1,"title":"Tivic Health Receives FDA Approval for Two Investigational New Drug Applications for Entolimod™ to Treat Acute Radiation Syndrome and Advanced Cancers","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TIVC\">Tivic Health</a> Receives FDA Approval for Two Investigational New Drug Applications for Entolimod™ to Treat Acute Radiation Syndrome and Advanced Cancers\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tivic Health Systems Inc. has announced the receipt of two investigational new drug <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a> applications for their lead candidate, Entolimod™, from <a href=\"https://laohu8.com/S/STAB\">Statera Biopharma</a>. These INDs are aimed at the treatment of acute radiation syndrome <a href=\"https://laohu8.com/S/ARS.UK\">$(ARS.UK)$</a> and advanced cancers. The transfer of these applications facilitates Tivic's engagement with the FDA to advance Entolimod along its regulatory pathway. This development enables the pursuit of clinical trials addressing conditions such as neutropenia and lymphocyte exhaustion. Tivic's CEO, Jennifer Ernst, emphasized the company's immediate focus on Entolimod's application for acute radiation syndrome, while also exploring its potential anti-tumor effects in advanced cancer scenarios.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tivic Health Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250820053049) on August 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tivic Health Receives FDA Approval for Two Investigational New Drug Applications for Entolimod™ to Treat Acute Radiation Syndrome and Advanced Cancers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTivic Health Receives FDA Approval for Two Investigational New Drug Applications for Entolimod™ to Treat Acute Radiation Syndrome and Advanced Cancers\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-20 20:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TIVC\">Tivic Health</a> Receives FDA Approval for Two Investigational New Drug Applications for Entolimod™ to Treat Acute Radiation Syndrome and Advanced Cancers\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tivic Health Systems Inc. has announced the receipt of two investigational new drug <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a> applications for their lead candidate, Entolimod™, from <a href=\"https://laohu8.com/S/STAB\">Statera Biopharma</a>. These INDs are aimed at the treatment of acute radiation syndrome <a href=\"https://laohu8.com/S/ARS.UK\">$(ARS.UK)$</a> and advanced cancers. The transfer of these applications facilitates Tivic's engagement with the FDA to advance Entolimod along its regulatory pathway. This development enables the pursuit of clinical trials addressing conditions such as neutropenia and lymphocyte exhaustion. Tivic's CEO, Jennifer Ernst, emphasized the company's immediate focus on Entolimod's application for acute radiation syndrome, while also exploring its potential anti-tumor effects in advanced cancer scenarios.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tivic Health Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250820053049) on August 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250820:nNDL4HZTRK:1","article_id":"2560105142","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2560105142","pubTimestamp":1755693066,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Tivic Health Receives FDA Approval for Two Investigational New Drug Applications for Entolimod to Treat Acute Radiation Syndrome and Advanced Cancers. Tivic Health Systems Inc. has announced the receipt of two investigational new drug  applications for their lead candidate, Entolimod, from Statera Biopharma. These INDs are aimed at the treatment of acute radiation syndrome  and advanced cancers. The transfer of these applications facilitates Tivic's engagement with the FDA to advance Entolimod along its regulatory pathway. This development enables the pursuit of clinical trials addressing conditions such as neutropenia and lymphocyte exhaustion. Tivic's CEO, Jennifer Ernst, emphasized the company's immediate focus on Entolimod's application for acute radiation syndrome, while also exploring its potential anti-tumor effects in advanced cancer scenarios.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","BK4139":"生物科技","TIVC":"Tivic Health Systems, Inc.","STAB":"Statera Biopharma Inc"},"translate_title":"Tivic Health获得FDA批准两项恩托莫德研究性新药申请™治疗急性放射综合征和晚期癌症","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TIVC":0.9,"STAB":0.9},"content_text":"Tivic Health Receives FDA Approval for Two Investigational New Drug Applications for Entolimod™ to Treat Acute Radiation Syndrome and Advanced Cancers\n    \n\n        Tivic Health Systems Inc. has announced the receipt of two investigational new drug $(IND.AU)$ applications for their lead candidate, Entolimod™, from Statera Biopharma. These INDs are aimed at the treatment of acute radiation syndrome $(ARS.UK)$ and advanced cancers. The transfer of these applications facilitates Tivic's engagement with the FDA to advance Entolimod along its regulatory pathway. This development enables the pursuit of clinical trials addressing conditions such as neutropenia and lymphocyte exhaustion. Tivic's CEO, Jennifer Ernst, emphasized the company's immediate focus on Entolimod's application for acute radiation syndrome, while also exploring its potential anti-tumor effects in advanced cancer scenarios.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tivic Health Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250820053049) on August 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2560105142","isCrawlerRequest":true}